NCT06681623Recruiting
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Source: ClinicalTrials.gov · Last updated 18 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 28 Oct 2024
- Start date
- 13 Aug 2024
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Neurology Center of New England P.C.
- Diseases
- Multiple sclerosis
- NCT number
- NCT06681623
What you commit to
- Study type: Observational
- Planned participants: 20
- From 13 Aug 2024 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received initial dose of ublituximab more than 6 months prior to study entry
- Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab
Other illness
- History of life-threatening infusion reaction on any anti-CD20 therapy
Other
- Active participation in an interventional clinical trial for MS
Who the study is looking for
- Signed informed consent
- Aged 55-80 years old
- Diagnosis of RMS according to the 2017 Revised McDonald criteria
- Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label
Age in the registry: 55 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neurology Center of New England P.C. Coordinator of this site? Confirm its status | Foxborough | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.